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Purpose: This study is part of a larger effort aiming to expand the knowledge of brain-enriched
proteins in human cerebrospinal fluid (CSF) and to provide novel insight into the relation
between such proteins and different neurodegenerative diseases.
Experimental design: Here 280 brain-enriched proteins in CSF from patients with Alzheimer’s
disease (AD), Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are profiled. In
total, 441 human samples of ventricular CSF collected post mortem and lumbar CSF collected
ante mortem are analyzed using 376 antibodies in a suspension bead array setup, utilizing a
direct labelling approach.
Results: Among several proteins displaying differentiated profiles between sample groups,
we focus here on two synaptic proteins, neuromodulin (GAP43) and neurogranin (NRGN).
They are both found at elevated levels in CSF from AD patients in two independent cohorts,
providing disease-associated profiles in addition to verifying and strengthening previously
observed patterns. Increased levels are also observed for patients for whom the AD diagnosis
was not established at the time of sampling.
Conclusions and clinical relevance: These findings indicate that analyzing the brain-enriched
proteins in CSF is of particular interest to increase the understanding of the CSF proteome and
its relation to neurodegenerative disorders. In addition, this study lends support to the notion
that measurements of these synaptic proteins could potentially be of great relevance in future
diagnostic tests for AD.
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Clinical Relevance
Increasing life expectancy leads to higher prevalence
of age-related diseases and as one of the most af-
fected organs, the aged brain is prone to deposition
of pathological proteins causing a variety of neurode-
generative disorders. Although many such proteins
have been well characterized, we still need to ex-
plore the potential pathophysiological influence from
yet other proteins. Utilizing patient-derived samples,
such studies can be conducted directly on brain tis-
sue or on cerebrospinal fluid (CSF). This study is part
of a larger effort aiming to expand the knowledge of
brain-enriched proteins in human CSF and to provide
novel insight into the relation between such proteins
and different neurodegenerative diseases. The actual
findings can extend our knowledge of the protein
content in the CNS and may also aid in the search for
novel diagnostic and therapeutic strategies for such
disorders.
1 Introduction
The human body is a complex system of cells, tissues, and
organs. By identifying the specialized genes and proteins re-
sponsible for specific cell and organ functions, we can in-
crease our understanding of human biology and the patho-
physiological processes associated with disease. Recent de-
velopments within the biotechnology field enable such large-
scale comparative studies where gene expression variability
can be investigated between and within tissues and organs.
Increasing life expectancy leads to higher prevalence of
age-related diseases [1]. The brain is one of the organs highly
affected by aging and age-related pathological processes give
rise to a variety of neurodegenerative disorders [2, 3]. Ex-
ploring protein expression, abundance, and distribution in
healthy and disease-affected brains will provide a possibility
to extend the current knowledge of the mechanisms involved
in neurological disorders. However, as the brain is well pro-
tected and only accessible through invasive surgery, direct
assessment of disease processes in living patients is limited.
This has led to the utilization of other biological samplemate-
rials with a proximity to the brain. Cerebrospinal fluid (CSF)
is one such material commonly used to monitor both normal
and pathological conditions of the human brain [4, 5]. Apart
from mechanically protecting the brain, CSF facilitates regu-
lation of neuronal activity through transport of neuropeptides
and hormones, as well as buffering of chemicals and proteins
diffused from the CNS [6, 7]. Changes in the brain are hence
reflected in the composition of CSF and it provides a mean
for studying processes related to neurological disease.
Several studies have aimed to determine the CSF pro-
teome, resulting in the identification of thousands of proteins
[4, 8, 9]. In order to gain insight into which of these proteins
that originate from cells in the CNS, efforts have been made
to map gene expression in different brain regions, as well as
comparing gene expression across tissues [10,11]. In a report
based on analysis of 32 different human tissues, the cere-
bral cortex was among the tissues with the largest number of
expressed genes and the study resulted in the identification
of 571 genes with enriched (5× higher expression compared
to all or the average of all other analyzed tissues) expression
in the brain [10]. Other global efforts to map tissue-specific
genes, such as the genotype–tissue expression (GTEx) project,
are continuously providing new data by including more tis-
sues and increasing sample numbers [12].
The correlation between mRNA levels and levels of the
corresponding protein product is by no means absolute as
protein levels are known to be greatly influenced by pre- and
posttranslational mechanisms that affect protein production,
stability, and turnover [13]. However, positive correlations
between mRNA and protein levels have been observed in
several human cell lines, as well as in tissues [14,15] and the
amount of present transcripts can be used as a predictor for
protein levels.
Neurodegenerative disorders constitute a group of dis-
eases involving progressive loss of neurons and neuronal
functions commonly associated with age. Among these,
Alzheimer’s disease (AD) is the most common, followed by
Parkinson’s disease (PD), vascular dementia, dementia with
Lewy bodies (DLB), and frontotemporal dementia [16]. These
diseases affect millions of people worldwide and further
characterization of the pathogenic and pathophysiological
mechanisms driving disease progression is necessary as the
current therapies are mainly limited to symptomatic treat-
ments. Herein, we describe a targeted study analyzing CSF
levels of a subset of the 571 proteins with mRNA expression
identified as brain-enriched [10]. Protein levels were detected
using a multiplexed suspension bead array with 376 antibod-
ies generated within the Human Protein Atlas (HPA) target-
ing 280 proteins in a total of 441 CSF samples from healthy
controls and patients with AD, PD, and DLB.
2 Materials and methods
2.1 CSF Samples
The samples analyzed in this study were derived from four
independent cohorts collected at different sites. Three of
the sample sets contained lumbar CSF collected from liv-
ing donors (antemortem) and the fourth ventricular CSF
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collected postmortem. Sample characteristics are summa-
rized in Table 1.
Samples from donors diagnosed with AD together with
matched controls were obtained from two independent
Swedish sample collections. In the first, CSF samples from
Uppsala University Hospital (denoted as AD1) were collected
via lumbar puncture as a part of the routine diagnostic proce-
dure and randomly chosen from a biobank collected during
2003–2007. Alzheimer cases had been diagnosed according to
the NINCDS-ADRDA (National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association) criteria and the
control samples had been collected from healthy volunteers.
For the second sample set, lumbar samples were collected at
the Sahlgrenska hospital in Gothenburg (denoted AD2). The
diagnostic criteria of each group was defined by a combina-
tion of clinical diagnosis (cognitively normal, mild-cognitive
impairment or dementia) and the CSF biomarker profile
including total A1-42, total Tau (t-Tau), and phospho-Tau
(p-Tau), measured using INNOTEST ELISAs (Fujirebio,
Ghent, Belgium) [17]. The CSF AD signature was defined
as abnormally decreased A1-42 for preclinical AD, and the
combination of decreased A1-42 together with increased T-
tau or P-tau for prodromal AD and dementia AD [17]. The
control group consisted of asymptomatic cognitively normal
individuals with all three core biomarkers within the normal
range. The Uppsala Ethical Review Board and the regional
ethics committee of the University of Gothenburg approved
the respective studies and all patients had given their in-
formed consents.
In the PD cohort, patients were clinically diagnosed ac-
cording to the United Kingdom PD Society Brain Bank
[18]. In addition, patients with progressive supranuclear
palsy or corticobasal syndrome, that is, “Parkinson plus”
variants, were included. Controls were suffering from be-
nign neurological conditions, such as tension headache
and unclassified sensory disturbances. The investigation
of the PD patients and the analysis of their CSF were
approved by the local ethic committees (2011/500-31/1;
2012/224-32/4). Informed consent was obtained from all
subjects.
An additional set of postmortem CSF samples (denoted
DLB) from patients with AD, DLB, and neurologically healthy
controls was included in the study. The samples were ob-
tained from the Netherlands Brain Bank, Netherlands Insti-
tute for Neuroscience (NBB), and cases were selected based
on neuropathological classifications with low comorbidity of
AD and DLB (Table 1). For detailed information on sample
collection, see Supporting Information.
2.2 Brain tissue
Human postmortem brain samples from ten AD patients
(AD Braak stage 6; amyloid deposits stage C) [19], ten DLB
patients (DLB Braak stage 5–6; amyloid deposits stage 0-B)
[20] and nine healthy controls (AD Braak stage 0–1; amyloid
deposits stage 0-B) were also obtained from NBB. The tis-
sue was received as formalin-fixed (4% formaldehyde) paraf-
fin embedded blocks of temporal cortex. Tissue microarrays
(4 m thick) were cut on a sliding microtome and mounted
onto glass slides coated with 3-aminopropyltriethoxysilane
(Sigma). The use of postmortem brain tissue and CSF sam-
ples was approved by the Stockholm ethical review board
(EPN 2013/474-31/12).
2.3 Protein profiling
2.3.1 Suspension bead array
Three hundred seventy-six HPA antibodies (www.
proteinatlas.org) targeting the 280 proteins with brain-
enriched mRNA expression levels were immobilized onto
color-coded magnetic beads as previously described [21]. Fol-
lowing immobilization, the coupled beads were washed and
stored in blocking reagent until creation of a suspension bead
array by combining all bead identities. All CSF samples were
cohort-wise transferred to 96-well microtiter plates in a ran-
domized layout, diluted 1:2, and directly labeled with biotin
as described elsewhere [22]. After labeling, the samples were
further diluted 1:8 and heat treated before incubationwith the
bead array at RT overnight. Captured proteins were detected
by addition of a streptavidin-conjugated fluorophore prior to
measurement in the FlexMap3D instrument (Luminex Cor-
poration). Results were reported as median fluorescence in-
tensities per bead identity and sample.
2.3.2 Immunohistochemistry
Tissuemicroarrays (TMA) of human temporal cortexwere de-
paraffinized, rehydrated, and treatedwith antigen retrieval so-
lution (pH6.0) and peroxidase block solution in an automated
Leica Bond RX immunostainer (Leica Biosystems). The
TMAs were thereafter incubated with primary antibodies for
16 h at 4C, washed, and blocked in Tris-NaCl-blocking buffer
(TNB) before addition of secondary antibodies. Following
this, tyramide signal amplification technology (TSA) cyanine
5 tyramide amplification reagent was added for 15min before
washing and quenching in 1%Sudan black. Fluorescencemi-
croscope images were acquired on a Vslide scanning micro-
scope (MetaSystems, Alltlussheim, Germany) equipped with
a CoolCube 2 camera, 2.5×, 5×, 10×, and 20× objectives and
filter sets for DAPI (EX350/50–EM470/40), FITC (EX493/16–
EM527/30), Cy3 (EX546/10–EM580/30), Cy3.5 (EX581/10–
EM617/40), and Cy5 (EX630/20–647/long pass).
For a more thorough description of the methods includ-
ing antibody validations such as sandwich immunoassays
and immunocapture multiple sclerosis (MS), see Supporting
Information.
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2.4 Data analysis
PCA was performed using the R function prcomp and
correlation coefficients for both proteins and protein levels
to clinical information were calculated using Spearman’s
rho statistics. Differences in protein levels between sample
groups were evaluated by the Wilcoxon rank-sum test
and unadjusted p values below 0.05 regarded as sig-
nificant. Existing datasets for gene expression in brain
from the HPA (www.proteinatlas.org) and GTEx portal
(www.gtexportal.org) was utilized for comparisons to protein
levels. For more detailed information on data analysis see
Supporting Information.
3 Results
Here, we report a multiplexed protein profiling using an
affinity-based proteomics approach to generate CSF profiles
of brain-enriched proteins. In a previous study, 571 of the in
total 13 992 genes expressed in human frontal cortex were
defined to have brain-enriched expression compared to other
human tissues. We analyzed 280 of the corresponding pro-
teins, targeted by 376 antibodies, in 441 CSF samples from
patients with AD, PD, and DLB as well as from neurologically
healthy and diseased controls (Fig. 1). Themajority of the pro-
teins included in this analysis are involved in neurotransmis-
sion, development, and neuronal processes such as learning,
memory, and cognition (Supporting Information Fig. 1).
3.1 Overview of protein profiles in CSF
A PCA of the data was performed to generate an overview of
the obtained sample profiles. The results indicate that profiles
from samples collected by lumbar puncture from patients in
the two AD and PD cohorts were, as expected, more simi-
lar to each other compared to the DLB sample set collected
from the lateral ventricles postmortem (Fig. 2A). In a com-
parison of intensities per antibody and cohort, 220 antibodies
displayed a significantly (p < 0.001) altered mean intensity
in this sample set compared to the cohorts collected through
lumbar puncture. Among the proteins with the largest differ-
ences were the highly expressed brain proteins glial fibrillary
acidic protein, myelin basic protein, and synaptosomal as-
sociated protein 25. Several proteins such as ermin, tubulin
polymerization-promoting protein, and numerous solute car-
rier proteins showed a lower relative expression in the DLB
cohort (Supporting Information Fig. 2).
To evaluate the concordance in protein levels between
different individuals and two gene expression datasets, the
frontal cortex HPA and GTEx data for 255 of the 280
proteins was compared, revealing a positive correlation of
 = 0.65 (Fig. 2B). To further investigate the relation of pro-
tein levels in our data to mRNA expression levels, the median
intensity per protein and sample collection was correlated to
the HPA FPKM (Fragments Per Kilobase of transcript per
Figure 1. Study overview. In this study, we profiled CSF sam-
ples with a focus on proteins with enriched expression in brain
compared to other human tissues. In total, 441 CSF samples rep-
resenting patients with Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD), and dementia with Lewy bodies (DLB) as well as con-
trols were analyzed using 376 antibodies targeting 280 proteins.
Disease-associated profiles were observed for the two proteins
neuromodulin (GAP43) and neurogranin (NRGN).
Million mapped reads) values and the GTEx RPKM (Reads
Per Kilobase of transcript per Million mapped reads) values.
Although no overall correlation was found ( < 0.18) a set
of 16 proteins represented by 22 antibodies with both high
mRNA expression and CSF levels (FPKM/RPKM above 5 and
median fluorescence intensities above 2000) could be distin-
guished from the majority of proteins in all four cohorts (Fig.
2C and D). Among these were amyloid-like protein 1, neuro-
modulin (GAP43), myelin-oligodendrocyte glycoprotein, se-
cretogranin 3, and beta-synuclein.
3.2 Variation of protein profiles with postmortem
delay
For the postmortem samples, the available information re-
garding postmortem delay (PMD) was used to investigate a
C© 2016 The Authors. PROTEOMICS – Clinical Applications Published by WILEY-VCH Verlag GmbH & Co. KGaA www.clinical.proteomics-journal.com
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Figure 2. Overview of pro-
tein profiles and comparisons
to mRNA expression. (A) An
overview of the obtained sam-
ple profiles was generated
through PCA. The result re-
vealed that protein levels in CSF
was found to be different in
the samples obtained as post-
mortem ventricular CSF com-
pared to lumbar CSF from living
donors. (B) Correlation between
HPA and GTEx mRNA expres-
sion levels (FPKM/RPKM) in hu-
man frontal cortex,p= 0.091. (C)
Correlation between mRNA ex-
pression levels (FPKM) acquired
within the HPA project and the
median fluorescent intensity ob-
tained in the CSF protein profil-
ing analysis for all studied co-
horts. The red dots represent
the 16 proteins with FPKM > 5
and median fluorescence inten-
sities> 2000. (D) Correlation be-
tween mRNA expression levels
(RPKM) acquired fromGTEx and
themedian fluorescent intensity
obtained in the CSF protein pro-
filing analysis for all studied co-
horts. The red dots represent the
16 proteins with RPKM > 5 and
median fluorescence intensities
> 2000.
potential correlation to the protein profiles. In total, 14 pro-
teins showed positive association to PMD ( > 0.4) with
the two proteins gamma-aminobutyric acid A receptor delta
and dendrin displaying the highest associations (Supporting
Information Table 1). Secretogranin 3 was the only protein
showing a negative association ( = −0.34), which is visually
presented together with the highest associations in Support-
ing Information Fig. 3.
3.3 CSF profiles of GAP43 and NRGN
In our data, levels of the two brain-enriched proteins GAP43
and neurogranin (NRGN) were found to be increased in CSF
of AD patients as compared to both controls and non-AD
MCI in the two independent sample cohorts (p < 0.05, Fig.
3A). Interestingly, patients defined as prodromal AD together
with individuals defined as preclinical ADwere found to have
higher levels of both GAP43 and NRGN. For GAP43, con-
cordant results were obtained with two different antibodies
targeting separate regions of the protein (HPA013392 and
HPA015600, see Supporting Information Fig. 4 for paired
antibody correlations). There were no significant differences
on protein level between sample groups in the PD cohort or
between AD, DLB, or controls in postmortem CSF for either
GAP43 or NRGN.
For samples from the two AD cohorts, clinical informa-
tion including age, and levels of A42, t-Tau, and p-Tau were
available. The obtained CSF protein levels for both GAP43
and NRGN in patients were correlated to all parameters in
order to investigate potential associations. For GAP43, posi-
tive correlations were found for both t-Tau and p-Tau (AD1
> 0.6, AD2 > 0.7) (Fig. 3B and C). For NRGN, a positive
trend was also observed for t-Tau and p-Tau, although with a
lower correlation coefficient (AD1 = 0.5, AD2 = 0.4 and 0.5,
respectively). No correlation was observed in relation to age
or A42 for either of the proteins. For the PD patients, clini-
cal information about the unified Parkinson’s disease rating
scale (UPDRS) was available and similarly used to study as-
sociations to GAP43 protein expression, revealing a negative
association between GAP43 levels and UPDRS ( = −0.4,
Supporting Information Fig. 5).
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Figure 3. Protein profiles of GAP43 and NRGN in CSF. (A) Protein profiles of GAP43 and NRGN visualized per sample group for all analyzed
samples. Stars indicate significant differences, *p < 0.05, **p < 0.01, ***p < 0.001. (B–C) Correlation of CSF protein levels of GAP43 and
NRGN to clinical parameters revealed positive associations to tau and P-tau levels for both proteins in two independent sample sets.
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Figure 4. Distribution of GAP43 and NRGN in
the human cerebral cortex. Immunohistochem-
istry staining of GAP43 and NRGN in a TMA
of human temporal cortex from one represen-
tative AD case (two left columns) and one con-
trol subject (two right columns). Both stainings
show synaptic-like pattern and the NRGN an-
tibody displayed additional staining of pyrami-
dal neurons. GAP43 and NRGN are visualized in
green, tau in red, and DAPI is shown in blue.
Scale bar = 50 m.
Apart from GAP43 and NRGN, several of the 280 studied
proteins revealed altered levels between sample groups
within the three studied diseases. These are at present
undergoing further evaluation and verification in additional
sample material in order to explore their relevance in relation
to disease pathology.
3.4 Distribution of GAP43 and NRGN in the human
cerebral cortex
Immunohistochemistry analysis of brain tissue using the
same antibodies as for CSF profiling revealed a synaptic-
like staining pattern for both GAP43 (both antibodies) and
NRGN with additional strong labeling of pyramidal-like cells
for NRGN (Fig. 4). Levels of NRGN immunoreactivity were
clearly reduced in tau-bearing cells in the AD brain.
4 Discussion
4.1 Overview of protein profiles in CSF
Profiles for all proteins in all samples were initially sum-
marized in a PCA, revealing an expected separation of the
postmortem ventricular samples from the three collections
of living donors. These samples differ with regard to two pa-
rameters: collection site (ventricular/lumbar) and time (ante-
mortem/postmortem). From our analysis, it is not possible to
conclude which parameter is the main cause of the observed
differences. However, as previous studies have shown, the
concentration of proteins derived from blood as well as total
protein concentration increase from the brain to the spine.
This is referred to as the rostro-caudal gradient and believed
to be the result of passive diffusion [23–26]. Brain-derived
proteins have, on the contrary, been reported to decrease in
concentration toward the spine [23]. This trend has not been
confirmed in all studies investigating this gradient [24, 27].
The proteins analyzed in our study were selected to be brain-
enriched and could therefore be considered as brain-derived
rather than blood-derived. The majority of proteins identified
with differences in ventricular postmortem versus lumbar
antemortem CSF was concordantly found with higher levels
in ventricular samples.
In postmortem brain tissue, the majority of transcripts
and proteins have been reported to be reasonably stable [28].
For CSF on the other hand, postmortem samples have been
shown to contain altered levels of proteins with an increase
compared to samples collected antemortem [29]. Finehout
et al., identified a set of proteins with positive correlation
to PMD (also referred to as postmortem interval), but none
with decreasing levels. This study did not include antibodies
against any of these proteins, although we found 14 other
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proteins that displayed a positive association to PMD and one
that displayed a negative association.
In order to properly investigate these differences between
the cohorts in our study and to be able to draw any conclu-
sions, additional samples exhibiting only one of the aspects
would have to be analyzed. This highlights the importance
of matching samples not only when it comes to age, gender,
and disease state, but also collection site and time as well as
postcollection treatment of the sample.
In order to compare protein profiles in CSF to gene ex-
pression in brain tissue, we performed a correlation analysis
of our results and data previously generated in two different
RNA sequencing efforts. The amount of expressed protein is
not solely dependent on the number of mRNA transcripts in
the corresponding tissue, but on several other factors such
as posttranslational processing and protein half-life [13]. The
low concordance inmRNAand protein levels between the two
different sample types is probablymainly explained by the fact
that themRNAdata and CSF protein data were acquired from
different individuals. Nevertheless, the high concordance in
expression between the HPA and the GTEx mRNA datasets
suggest that relative expression levels are fairly consistent
between individuals, strengthening the selection of protein
targets for this study.
4.2 CSF profiles of GAP43 and NRGN
We found protein levels of both GAP43 and NRGN in CSF to
be significantly increased in AD patients as compared to con-
trols and non-AD MCI in both cohorts with CSF from living
donors. Interestingly, increased levels were also observed for
patients forwhom theADdiagnosiswas not established at the
time of sampling (denoted preclinical, prodromalAD, andAD
converters). Although levels were increased in AD CSF from
both independent cohorts, neither GAP43 nor NRGN were
found at altered levels in AD samples collected postmortem.
While these were not among the proteins with the largest
differences between cohorts, they were both found with in-
creased levels in the DLB cohort as compared to the others.
This finding could possibly indicate a leakage of proteins
from tissue to CSF, masking any potential biological differ-
ence and thus explain why disease-associated levels were not
observed in this cohort.
Despite the fact that no differences were found in protein
levels for either GAP43 or NRGN in CSF from PD patients
and controls, protein profiles were correlated to the clinical
information available. Rating of patients according to the UP-
DRS scale that is used to monitor PD-related disabilities and
impairment with higher scores indicating higher disability
[30] revealed a weak negative association to GAP43 CSF lev-
els. This could indicate that patients with progressive disease
display lower levels of GAP43, in contrast to the increased lev-
els in AD patients. However, as PD is characterized by amore
specific degradation of the dopaminergic neurons mainly in
the substantia nigra [31], there is a possibility that the general
tissue degradation occurring in PD is not extensive enough
to be detected in CSF. So far, GAP43 has not been widely
studied in relation to PD but one study indicated decreased
levels in CSF from PD patients compared to controls [32].
GAP43 is a synaptic protein mainly observed in the presy-
naptic terminals. It has been shown to play a crucial role in
neuronal development and axonal growth [33, 34] by mod-
ulating the assembly of filamentous actin in growth cones
[35] and regulating the interaction between microtubule and
actin during spindle formation [36]. Protein levels of GAP43
decrease in frontal cortex and hippocampus of AD patients
but have also previously been observed to increase in CSF
[32,37,38]. GAP43 is secreted into CSF from the brain and has
been studied using affinity-based proteomics in the context
of both MS and AD [39]. In MS, just as for the PD data pre-
sented above, CSF levels were found to decrease with disease
progression [22,40]. NRGN is a postsynaptic protein thought
to be involved in pathways affecting synaptic plasticity by reg-
ulating levels of calmodulin [41]. Several independent studies
have shown that the CSF concentration of NRGN is increased
in AD [42–46] similarly to the results shown here. Further-
more, the expression pattern seems to be specific for AD
[47] and levels of NRGN have also been suggested to pre-
dict future cognitive decline, brain atrophy, and reduction in
glucose metabolism in the prodromal disease stages [48, 49].
Loss of synapses is an early event in AD that can be detected
already in MCI patients and correlates well with cognitive
dysfunction [38, 50, 51]. One could consequently speculate
that the increase of GAP43 and NRGN levels demonstrated
in previous studies, as well as in the current study, is due
to leakage of GAP43 and NRGN into the CSF as a result of
synaptic degradation. However, an initial increase of synaptic
proteins during the earlier AD stages has been observed and
is thought to be part of possible adaptive response to the loss
of synapses [52]. The increase of GAP43 and NRGN could
hence also be an indication of an adaptive response system
following the synaptic loss.
In our assay, two independent antibodies targeting dif-
ferent regions of the protein was used to assess the levels
of GAP43 in both CSF and cerebral cortex. These antibod-
ies showed highly concordant results, strengthening the data
generated in our analysis. For the two synaptic proteins dis-
cussed above, we observed similar results in the comparison
of patients and controls as well as a positive correlation inCSF
protein levels ( = 0.52–0.85 for NRGN correlated against
both GAP43 antibodies in all four cohorts, data not shown).
It has previously been reported that GAP43 and NRGN share
sequence similarities [53] and one of the GAP43 antibodies
was raised against part of the shared sequence (Supporting
Information Fig. 6). Therefore, a sandwich assay was per-
formed in order to investigate potential cross-reactivity for
the two proteins. The assay was performed with all antibodies
targeting GAP43 and NRGN as both capture and detection
antibodies and the results showed no indication of cross-
reactivity (Supporting Information Fig. 7). Furthermore, an
immunocapture MS experiment was performed to confirm
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the selectivity of the antibodies. All antibodies where shown
to capture their intended target with a sequence coverage
of identification of 74 and 19% for GAP43 and NRGN,
respectively (Supporting Information Fig. 8 and Support-
ing Information Table 2). The enrichment of GAP43 by
HPA013392 and HPA015600 was highly specific and ex-
clusive, whereas HPA038171 captured NRGN together with
TBC1D10C, C1QBN, and IgG (L chain) (Supporting Infor-
mation Fig. 9), which could be due to lower levels of NRGN
in CSF compared to GAP43. Nevertheless, together these
observations show that the utilized antibodies do not cross-
react and that the measured levels indeed correspond to the
intended target in the presented CSF assay.
4.3 Distribution of GAP43 and NRGN in the human
cerebral cortex
Immunohistochemistry analysis of brain tissue confirmed a
synaptic-like staining pattern for both GAP43 and NRGN as
would be expected based on previous publications. In addi-
tion, the NRGN antibody displayed strong staining of pyra-
midal cells as has also been shown before [54]. GAP43 has
previously been reported to stain neuronal soma [55], but no
such staining could be confirmed in our experiments. This
could be due to differences in the used brain regions between
this and the aforementioned study as well as which cortical
layers that were present in the TMA. Using the current setup,
we did not detect a clear difference in staining patterns of nei-
ther GAP43 nor NRGN between AD patients and controls.
Previous reports indicate a decrease in some regions of AD
brains, although these findings have not been replicated in all
studies [55, 56]. In order to properly assess differential levels
of GAP43 and NRGN in brain tissue, analysis of larger brain
sections from several patients would have to be performed.
5 Conclusions
This is to our knowledge the first extensive study of brain-
enriched proteins in human CSF. Through the established
affinity proteomics platform for protein profiling, we were
able to analyze 280 proteins in 441 human samples. This sam-
ple throughput enabled comparative profiling both within
and between three of our most common neurological disor-
ders and allowed for exploration of protein levels in relation
to RNA expression in brain as well as to relevant clinical
information.
In this paper, we present a verification of disease-
associated profiles of both GAP43 and NRGN and further-
more strengthen their potential as biomarkers in the con-
text of AD, using two independent sample materials. Besides
these two, several of the 280 studied proteins displayed al-
tered levels between samples groups both within AD, PD,
and DLB. These proteins are currently undergoing contin-
ued evaluation including verification in additional sample
collections to establish their potential role in the respective
disease contexts. Meanwhile, we believe that the information
presented here can greatly contribute to increase in the under-
standing of brain-enriched proteins in CSF and their relation
to pathological states of the human brain.
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